Results 251 to 260 of about 58,085 (295)
Some of the next articles are maybe not open access.
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
Current Opinion in Nephrology and Hypertension, 2015Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs approved for the treatment of type 2 diabetes. The main action of DPP-4 inhibitors is to increase the level of incretin hormones such as glucagon-like peptide-1 (GLP-1), thereby stimulating insulin secretion from pancreatic β cells.
Yuichi, Makino +2 more
openaire +2 more sources
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species.
Juan M, Betancort +12 more
openaire +2 more sources
Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience
Diabetes Technology & Therapeutics, 2012According to the latest American Diabetes Association guidelines, lowering glycated hemoglobin (HbA(1c)) to below or around 7% has been shown to reduce microvascular and neuropathic complications of diabetes and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease. Recently a new class of
DEROSA, GIUSEPPE, MAFFIOLI, PAMELA
openaire +3 more sources
Context-dependent effects of dipeptidyl peptidase 4 inhibitors
Current Opinion in Nephrology and Hypertension, 2016The antidiabetic mechanism of dipeptidyl peptidase 4 (DPP4) inhibitors is attributed to attenuation of incretin metabolism. Because DPP4 has at least 45 substrates, context-dependent off-target effects of DPP4 inhibitors are likely. Here, we consider the clinical ramifications of the context-dependent effects of DPP4 inhibitors.Although incretins ...
openaire +2 more sources